PMID- 24029046
OWN - NLM
STAT- MEDLINE
DCOM- 20140106
LR  - 20131220
IS  - 1421-9662 (Electronic)
IS  - 0001-5792 (Linking)
VI  - 131
IP  - 1
DP  - 2014
TI  - Comparative study of the efficacy of allogeneic hematopoietic stem cell 
      transplantation from human leukocyte antigen-haploidentical related and unrelated 
      donors in the treatment of leukemia.
PG  - 37-44
LID - 10.1159/000353776 [doi]
AB  - AIMS: To compare the efficacy of hematopoietic stem cell transplantation (HSCT) 
      from human leukocyte antigen (HLA)-haploidentical related donors (RD) and 
      unrelated donors (URD) in the treatment of leukemia. METHODS: Ninety-three 
      leukemia patients underwent allogeneic HSCT were divided into two groups: 51 
      cases of RD-HSCT and 42 cases of URD-HSCT. In the RD-HSCT group, a 
      preconditioning regimen with fludarabine (Flu) + busulfan (Bu) + cytosine 
      arabinoside (Ara-C) was used in 42 patients and total body irradiation (TBI) + 
      Flu + Ara-C was used in the remaining 9. RESULTS: In the URD-HSCT group, a 
      modified preconditioning regimen with Bu + cyclophosphamide was used in 35 
      patients, while the other 7 patients underwent treatment with TBI + Flu. After 
      transplantation, the occurrence rate of grade II-IV acute graft-versus-host 
      disease (GVHD) was 46.0 and 51.2% in the two groups. Likewise, the rate of 
      chronic GVHD was 46.0 and 63.4%, respectively. No significant differences in the 
      occurrence of acute and chronic GVHD were detected between the two groups. The 
      differences in early-stage infection rate after transplantation, recurrence rate, 
      3-year survival rate, and disease-free survival rate between the two groups were 
      not significant. CONCLUSION: HLA-haploidentical RD-HSCT with enhanced 
      preconditioning and administration of immunosuppressants showed a clinical 
      efficacy similar to that of URD-HSCT against leukemia, without the risk of 
      increased infection and GVHD.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
FAU - Yang, Kai
AU  - Yang K
AD  - Department of Hematology, Beijing Military General Hospital, Beijing, China.
FAU - Si, Yingjian
AU  - Si Y
FAU - Chen, Huiren
AU  - Chen H
FAU - He, Xuepeng
AU  - He X
FAU - Lou, Jinxing
AU  - Lou J
FAU - Bai, Xue
AU  - Bai X
FAU - Du, Junfeng
AU  - Du J
FAU - Guo, Zhi
AU  - Guo Z
FAU - Chen, Peng
AU  - Chen P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20130911
PL  - Switzerland
TA  - Acta Haematol
JT  - Acta haematologica
JID - 0141053
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - China/epidemiology
MH  - Female
MH  - Graft vs Host Disease/epidemiology/mortality
MH  - HLA Antigens/*immunology
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/mortality
MH  - Humans
MH  - Leukemia/*therapy
MH  - Male
MH  - Middle Aged
MH  - Transplantation Conditioning
MH  - *Unrelated Donors
EDAT- 2013/09/14 06:00
MHDA- 2014/01/07 06:00
CRDT- 2013/09/14 06:00
PHST- 2012/12/13 00:00 [received]
PHST- 2013/06/17 00:00 [accepted]
PHST- 2013/09/14 06:00 [entrez]
PHST- 2013/09/14 06:00 [pubmed]
PHST- 2014/01/07 06:00 [medline]
AID - 000353776 [pii]
AID - 10.1159/000353776 [doi]
PST - ppublish
SO  - Acta Haematol. 2014;131(1):37-44. doi: 10.1159/000353776. Epub 2013 Sep 11.